First Patient Dosed in the NIB103 Phase I Clinical Trial
Noile-Immune Biotech Inc. (co-developing the product in Japan with TAKARA BIO INC.)
Japan; NIB103 (PRIME CAR-T cells)
Fiscal year ending December 2026
The impact of this matter on the Company's results for the fiscal year ending December 2026 is expected to be minor. The Company will promptly disclose any matters requiring disclosure in the future.
Based on the results of this trial, the Company plans to conduct the subsequent clinical trials required. The Company will promptly disclose any matters requiring disclosure in the future.
| Item | Details |
|---|---|
| Event name | First Patient Dosed in the NIB103 Phase I Clinical Trial |
| Subject Entity | Noile-Immune Biotech Inc. (co-developing the product in Japan with TAKARA BIO INC.) |
| Target Locations / Products | Japan; NIB103 (PRIME CAR-T cells) |
| Accounting period in which recognized | Fiscal year ending December 2026 |
| Impact on Earnings Forecast | The impact of this matter on the Company's results for the fiscal year ending December 2026 is expected to be minor. The Company will promptly disclose any matters requiring disclosure in the future. |
| Outlook | Based on the results of this trial, the Company plans to conduct the subsequent clinical trials required. The Company will promptly disclose any matters requiring disclosure in the future. |
| Planned follow-up disclosure | The Company will promptly disclose any matters requiring disclosure in the future. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for dosing is stated. The trial is intended primarily to evaluate safety and tolerability, with antitumor efficacy and cellular kinetics as secondary endpoints.